Order Article Reprints

Hwangbo H, Kim MY, Ji SY, Kim SY, Lee H, Kim G-Y, Park C, Keum Y-S, Hong SH, Cheong J, et al. Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro. Antioxidants. 2020; 9(11):1040. https://doi.org/10.3390/antiox9111040

Hwangbo, Hyun, Min Yeong Kim, Seon Yeong Ji, So Young Kim, Hyesook Lee, Gi-Young Kim, Cheol Park, Young-Sam Keum, Su Hyun Hong, Jaehun Cheong, and et al. 2020. "Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro" Antioxidants 9, no. 11: 1040. https://doi.org/10.3390/antiox9111040

Hwangbo, H., Kim, M. Y., Ji, S. Y., Kim, S. Y., Lee, H., Kim, G.-Y., Park, C., Keum, Y.-S., Hong, S. H., Cheong, J., & Choi, Y. H. (2020). Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro. Antioxidants, 9(11), 1040. https://doi.org/10.3390/antiox9111040